Abstract RF3-07: ROSCO: Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: Randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil,Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy
Year: 2025
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Daniel Rea, S. Pirrie, L. Hayward, S. Chan, M. Varughese, S. Spensley, U. Barthakur, M. MacKenzie, S. J. Bowden, C. Gaunt, E. Southgate, N. Nicholson, P. Wetherell, M. Soden, L. Billingham, C. Brookes, D. Cameron, J. Starczynski, J. Dowds. H. Earl, R. Stein, A. Graham, A. Shaaban, S. McIntosh, F. Raja, J. Abraham, K. Taylor, T. Piper, Z. Billyeald, D. Wheatley, J. Bartlett
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4411290828